Accounts Payable (Quarterly) Chart

View Accounts Payable (Quarterly) for ABBV.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Accounts Payable (Quarterly) Chart
Start Trial

Historical Accounts Payable (Quarterly) Data

View and export this data back to 2011. Start Trial.
Date Value
March 31, 2026 33.61B
December 31, 2025 34.42B
September 30, 2025 33.36B
June 30, 2025 31.83B
March 31, 2025 30.96B
December 31, 2024 31.91B
September 30, 2024 30.40B
June 30, 2024 29.30B
March 31, 2024 31.26B
December 31, 2023 30.52B
September 30, 2023 29.57B
June 30, 2023 26.90B
March 31, 2023 24.65B
December 31, 2022 2.934B
September 30, 2022 23.39B
June 30, 2022 22.48B
March 31, 2022 22.53B
December 31, 2021 2.882B
September 30, 2021 21.83B
June 30, 2021 20.70B
March 31, 2021 20.49B
December 31, 2020 19.84B
September 30, 2020 19.33B
June 30, 2020 19.24B
March 31, 2020 12.70B
Date Value
December 31, 2019 11.66B
September 30, 2019 12.03B
June 30, 2019 11.14B
March 31, 2019 11.67B
December 31, 2018 11.90B
September 30, 2018 11.34B
June 30, 2018 10.65B
March 31, 2018 10.54B
December 31, 2017 10.07B
September 30, 2017 8.911B
June 30, 2017 8.711B
March 31, 2017 8.364B
December 31, 2016 9.341B
September 30, 2016 9.047B
June 30, 2016 8.70B
March 31, 2016 8.132B
December 31, 2015 8.442B
September 30, 2015 8.028B
June 30, 2015 7.222B
March 31, 2015 6.426B
December 31, 2014 6.891B
September 30, 2014 6.073B
June 30, 2014 6.008B
March 31, 2014 6.125B
December 31, 2013 6.375B

Accounts Payable Definition

Accounting terminology for money that a company owes to vendors for services or products that it purchased on credit. Accounts payable appear on the balance sheet as a current liability.

Read full definition.

Accounts Payable (Quarterly) Range, Past 5 Years

View Accounts Payable (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Accounts Payable (Quarterly) Benchmarks

View Accounts Payable (Quarterly) Benchmarks
Start Trial
Biogen, Inc. 358.50M
Gilead Sciences, Inc. 645.00M
Regeneron Pharmaceuticals, Inc. 1.027B
Travere Therapeutics, Inc. 12.91M
Amgen, Inc. 2.935B